Cyclopharm Says Technegas Technology Approved for Use at National Institutes of Health in Maryland
MT Newswires Live
Feb 18
Cyclopharm (ASX:CYC) said that its Technegas technology, which provides high-resolution ventilation imaging at the site where oxygen is taken up in the lung, was approved for clinical use at the National Institutes of Health (NIH) in Bethesda, Maryland, according to a Wednesday Australian bourse filing.
The firm received a formal purchase order, and installation is expected in the coming weeks. The technology will be used for clinical ventilation imaging within NIH's protocol-driven clinical program.
The contract leverages the firm's five-year federal supply schedule agreement, which provides streamlined procurement access across US federal healthcare institutions.
Its shares rose 1% in recent trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.